BR0207933A - Mutantes de interleucina-18, sua produção e uso - Google Patents

Mutantes de interleucina-18, sua produção e uso

Info

Publication number
BR0207933A
BR0207933A BR0207933-0A BRPI0207933A BR0207933A BR 0207933 A BR0207933 A BR 0207933A BR PI0207933 A BRPI0207933 A BR PI0207933A BR 0207933 A BR0207933 A BR 0207933A
Authority
BR
Brazil
Prior art keywords
mutants
interleukin
production
molecule
wild type
Prior art date
Application number
BR0207933-0A
Other languages
English (en)
Inventor
Charles Dinarello
Soo-Hyun Kim
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of BR0207933A publication Critical patent/BR0207933A/pt
Publication of BRPI0207933B1 publication Critical patent/BRPI0207933B1/pt
Publication of BRPI0207933B8 publication Critical patent/BRPI0207933B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MUTANTES DE INTERLEUCINA-18, SUA PRODUçãO E USO". A invenção refere-se a mutantes de IL-18 com afinidade menor com IL-18BP do que a molécula de IL-18 do tipo selvagem.
BR0207933-0 2001-03-08 2002-03-08 polipeptídeo mutante de interleucina-18 e composição farmacêutica BRPI0207933B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27432701P 2001-03-08 2001-03-08
US60/274,327 2001-03-08
PCT/IB2002/002344 WO2002101049A2 (en) 2001-03-08 2002-03-08 Interleukin-18 mutants, their production and use

Publications (3)

Publication Number Publication Date
BR0207933A true BR0207933A (pt) 2004-03-02
BRPI0207933B1 BRPI0207933B1 (pt) 2020-11-24
BRPI0207933B8 BRPI0207933B8 (pt) 2021-05-25

Family

ID=23047735

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207933-0 BRPI0207933B8 (pt) 2001-03-08 2002-03-08 polipeptídeo mutante de interleucina-18 e composição farmacêutica

Country Status (19)

Country Link
US (2) US7524488B2 (pt)
EP (1) EP1392830B1 (pt)
JP (1) JP2004530432A (pt)
KR (1) KR100862136B1 (pt)
CN (1) CN100503829C (pt)
AT (1) ATE315647T1 (pt)
AU (1) AU2002324249B2 (pt)
BR (1) BRPI0207933B8 (pt)
CA (1) CA2438851C (pt)
DE (1) DE60208692T2 (pt)
DK (1) DK1392830T3 (pt)
EA (1) EA005769B1 (pt)
ES (1) ES2251610T3 (pt)
HK (1) HK1084151A1 (pt)
IL (2) IL157800A0 (pt)
MX (1) MXPA03008110A (pt)
SI (1) SI1392830T1 (pt)
UA (1) UA79235C2 (pt)
WO (1) WO2002101049A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4842128B2 (ja) * 2003-07-21 2011-12-21 トランジェーヌ、ソシエテ、アノニム 新規多機能性サイトカイン
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ME01198B (me) * 2003-11-05 2013-03-20 Ares Trading Sa Prečišćavanje il-18 vezujućeg proteina
US7557084B2 (en) * 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
DK2267024T3 (da) 2005-06-03 2012-06-25 Ares Trading Sa Fremstilling af rekombinant II-18 bindingsprotein
SI1891088T1 (sl) 2005-06-10 2012-02-29 Ares Trading Sa Postopek za äśiĺ äśenje il-18 vezavnega proteina
CN101177454B (zh) * 2007-05-09 2010-09-22 郑骏年 Il-18突变体多肽及制备及用途
WO2012078936A2 (en) * 2010-12-10 2012-06-14 Glaxosmithkline Llc Methods to produce a purified peptide chain fraction
WO2019051015A1 (en) * 2017-09-06 2019-03-14 Yale University VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE
JP2021170968A (ja) * 2020-04-22 2021-11-01 国立大学法人 長崎大学 マウスｉｌ−１８の製造方法及びそのための組換えｄｎａ
IL300638A (en) * 2020-08-19 2023-04-01 Bright Peak Therapeutics Modified IL-18 polypeptides and uses thereof
WO2022094473A1 (en) 2020-11-02 2022-05-05 Simcha IL-18, Inc. Interleukin-18 variants and methods of use
JPWO2022172944A1 (pt) * 2021-02-10 2022-08-18
US20230146665A1 (en) 2021-07-27 2023-05-11 Xencor, Inc. Il-18-fc fusion proteins
JP2023024168A (ja) 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
WO2023056193A2 (en) * 2021-09-29 2023-04-06 Chimera Bioengineering, Inc. Il-18 variants and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
WO2023161854A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
US20230357342A1 (en) * 2022-02-23 2023-11-09 Bright Peak Therapeutics Ag Modified il-18 polypeptides
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
IL129427A0 (en) 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules

Also Published As

Publication number Publication date
CA2438851A1 (en) 2002-12-19
CN1764723A (zh) 2006-04-26
BRPI0207933B1 (pt) 2020-11-24
JP2004530432A (ja) 2004-10-07
WO2002101049A2 (en) 2002-12-19
AU2002324249B2 (en) 2007-04-05
US20090286855A1 (en) 2009-11-19
CN100503829C (zh) 2009-06-24
MXPA03008110A (es) 2003-12-12
KR20030088448A (ko) 2003-11-19
ES2251610T3 (es) 2006-05-01
EP1392830B1 (en) 2006-01-11
US7875709B2 (en) 2011-01-25
WO2002101049A3 (en) 2003-12-18
EA200300987A1 (ru) 2004-02-26
IL157800A0 (en) 2004-03-28
SI1392830T1 (sl) 2006-06-30
US20020169291A1 (en) 2002-11-14
EA005769B1 (ru) 2005-06-30
DK1392830T3 (da) 2006-05-08
US7524488B2 (en) 2009-04-28
DE60208692T2 (de) 2006-07-13
IL157800A (en) 2009-08-03
ATE315647T1 (de) 2006-02-15
UA79235C2 (en) 2007-06-11
HK1084151A1 (en) 2006-07-21
CA2438851C (en) 2011-07-26
DE60208692D1 (de) 2006-04-06
KR100862136B1 (ko) 2008-10-09
BRPI0207933B8 (pt) 2021-05-25
EP1392830A2 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
BR0207933A (pt) Mutantes de interleucina-18, sua produção e uso
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
RS50477B (sr) Anti-il-12 antitela, kompozicije, metode i njihove upotrebe
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
WO2001064835A8 (en) Novel nucleic acids and polypeptides
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
ATE347057T1 (de) Federelement
NO20040022L (no) Slitesammenstilling
ID23374A (id) Halogenopirimidin
DE60206272D1 (de) Chelatorkonjugate mit verbesserten eigenschaften
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO2001064834A8 (en) Novel nucleic acids and polypeptides
DE60109430D1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
DE69935782D1 (de) Brustkrebsresistenzprotein (bcrp) und für dieses kodierende dna
DK1363944T3 (da) Höjaffinitetsantagonister for ELR-CXC-kemokiner
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs
ES2192034T3 (es) Feniluracilos substituidos con efecto herbicida.
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
MXPA05007793A (es) Composiciones de nucleotidos enlazados con alquilo.
WO2005057486A3 (en) Protein engineering with analogous contact environments
DK1196607T3 (da) Antibakterielt chlamysin B-protein, gen kodende derfor samt ekspressionssystem
ATE372788T1 (de) Kontrastmittel bestehend aus geometrisch hochgeordneten proteinen für die medizinische diagnostik
ATE405668T1 (de) Exopolysaccharidproduktion
WO2001064840A8 (en) Novel bone marrow nucleic acids and polypeptides

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ARES TRADING S.A. (CH)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME REQUERIDO NA PETICAO NO 055209/RJ DE 27/09/2004.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/03/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.